Logowanie
Zarejestruj się
Zresetuj hasło
Publikuj i Dystrybuuj
Rozwiązania Wydawnicze
Rozwiązania Dystrybucyjne
Dziedziny
Architektura i projektowanie
Bibliotekoznawstwo i bibliologia
Biznes i ekonomia
Chemia
Chemia przemysłowa
Filozofia
Fizyka
Historia
Informatyka
Inżynieria
Inżynieria materiałowa
Językoznawstwo i semiotyka
Kulturoznawstwo
Literatura
Matematyka
Medycyna
Muzyka
Nauki farmaceutyczne
Nauki klasyczne i starożytne studia bliskowschodnie
Nauki o Ziemi
Nauki o organizmach żywych
Nauki społeczne
Prawo
Sport i rekreacja
Studia judaistyczne
Sztuka
Teologia i religia
Zagadnienia ogólne
Publikacje
Czasopisma
Książki
Materiały konferencyjne
Wydawcy
Blog
Kontakt
Wyszukiwanie
EUR
USD
GBP
Polski
English
Deutsch
Polski
Español
Français
Italiano
Koszyk
Home
Czasopisma
Asian Biomedicine
Tom 16 (2022): Zeszyt 2 (April 2022)
Otwarty dostęp
Atorvastatin reduces alloxan-induced impairment of aversive stimulus memory in mice
Osman Kukula
Osman Kukula
oraz
Caner Günaydın
Caner Günaydın
| 29 kwi 2022
Asian Biomedicine
Tom 16 (2022): Zeszyt 2 (April 2022)
O artykule
Poprzedni artykuł
Następny artykuł
Abstrakt
Artykuł
Ilustracje i tabele
Referencje
Autorzy
Artykuły w tym zeszycie
Podgląd
PDF
Zacytuj
Udostępnij
Article Category:
Original article
Data publikacji:
29 kwi 2022
Zakres stron:
71 - 78
DOI:
https://doi.org/10.2478/abm-2022-0009
Słowa kluczowe
alloxan
,
atorvastatin
,
avoidance learning
,
diabetes mellitus
,
experimental
,
memory
© 2022 Osman Kukula et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Figure 1
(A) Mouse weight throughout the experiment analyzed with a general linearized model. #P < 0.05, ###P < 0.001 alloxan-induced diabetes vs. vehicle control. ***P < 0.001 liraglutide + alloxan-induced diabetes vs. alloxan-induced diabetes. (B) Blood glucose levels after oral glucose administration for each experimental group in the OGTT. (C) Locomotor activity for each experimental group. Statistical analyses were conducted using a one-way ANOVA with a Tukey post hoc test. Data are represented as mean ± standard deviation. ANOVA, analysis of variance; Ator, atorvastatin; Control, saline vehicle treatment alone as a negative control; DM, alloxan-induced model of diabetes mellitus; OGTT, oral glucose tolerance test.
Figure 2
Effect of each drug treatment on (A) initial latency and (B) retention period latency in the passive avoidance test. There were no significant differences in initial latency between experimental groups. Alloxan-induced diabetes significantly decreased retention period latency. #P < 0.05 vs. vehicle control. Atorvastatin significantly attenuated the alloxan-induced diabetes decrease in retention period latency. *P < 0.05 vs. alloxan-induced diabetes; +P < 0.05 vs. alloxan-induced diabetes + liraglutide. Liraglutide also significantly attenuated the alloxan-induced diabetes decrease in retention period latency even more than atorvastatin. ***P < 0.001. Symbols represent each data point and the bar indicates mean ± standard deviation. Statistical analyses were performed using a Kruskal–Wallis test. Ator, atorvastatin; Control, saline vehicle treatment alone as a negative control; DM, alloxan-induced model of diabetes mellitus.
Figure 3
The amount of time spent in the dark compartment by mice in each experimental group. Alloxan-induced diabetes significantly increased the time spent in the dark compartment. #P < 0.05 vs. saline vehicle control. Atorvastatin attenuated this increase in mice with alloxan-induced diabetes. *P < 0.05 vs. alloxan-induced diabetes; +P < 0.05 vs. alloxan-induced diabetes + liraglutide. Liraglutide significantly attenuated the time mice with alloxan-induced diabetes spent in the dark compartment. ***P < 0.001 vs. alloxan-induced diabetes. Symbols represent each data point and the bars indicate mean ± standard deviation. Statistical analyses were performed using a one-way ANOVA with a Tukey post hoc test. ANOVA, analysis of variance; Ator, atorvastatin; Control, saline vehicle treatment alone as a negative control; DM, alloxan-induced model of diabetes mellitus.
Podgląd